How often are you recommending adjuvant pembrolizumab for resected stage IIB/C melanoma patients?

Will refer to the results from the KEYNOTE-716 trial:

The data cutoff for the analysis (in January 2022), median follow-up was 27.4 months (interquartile range = 23.1–31.7 months). Pembrolizumab significantly improved distant metastasis–free survival vs placebo (hazard ratio [HR] = 0.64, 95% confiden...

The patient should be enrolled on KEYNOTE-716 (Phase 3 study of pembro vs placebo for high risk stage II melanoma including T3b, T4a, T4b) - https://clinicaltrials.gov/ct2/show/NCT03553836?term=KEYNOTE+716&rank=1.